Aligos Therapeutics, Inc. (ALGS)
After hours:
| Previous Close | 0.8290 |
| Open | 0.8100 |
| Bid | 0.7796 x 300 |
| Ask | 0.8312 x 300 |
| Day's Range | 0.7820 - 0.8290 |
| 52 Week Range | 0.5390 - 1.3800 |
| Volume | |
| Avg. Volume | 401,696 |
| Market Cap | 61.897M |
| Beta (5Y Monthly) | 2.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3600 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
GlobeNewswireAligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced an ePoster flash session presentation at the 34th European Society
- GlobeNewswire
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, wishes to express its condolences on the recent passing of Stephen A. Harrison, MD., Col (Ret.), FAASLD, who served as a trusted advisor and the Principal Investigator for the Company’s ongoing Phase 2a HERALD study in metabolic dysfunction
- GlobeNewswire
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that management will participate in one-on-one meetings at the Piper Sandler Spring Biopharma Symposium 2024 being held in Boston, Massachusetts on April 16-17, 2024. Please contact your Piper Sandler representative to sched
